Zobrazeno 1 - 10
of 938
pro vyhledávání: '"Frances A, Shepherd"'
Autor:
Armando Santoro, Garrido Pilar, Daniel S.W. Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R. Overbeck, Enriqueta Felip, Can Cai, Eddy Simantini, Tracey McCulloch, Eric S. Schaefer
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Despite promising outcomes of treatment with anti-programmed cell death (PD)-1/PD-ligand (L)1 agents in combination with platinum-doublet chemotherapy (PDC) in the first-line setting, a significant unmet medical need remains in pa
Externí odkaz:
https://doaj.org/article/49d4a4474e494f5081ff231d7fc7b4f8
Autor:
Shelley Kuang, Kaitlin Chen, Sachin Sayal, Gajeni Prabahan, Mary R. Rabey, Lisa W. Le, Andrew Seto, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Adrian G. Sacher, Jennifer H. Law, Peter Sabatini, Tracy L. Stockley, Ming S. Tsao, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4476-4485 (2024)
In advanced non-squamous non-small-cell lung cancer (NSCLC), routine testing with next-generation sequencing (NGS) is recommended to identify actionable genomic alterations (AGAs). The therapeutic implications of repeated NGS testing on synchronous a
Externí odkaz:
https://doaj.org/article/b1046990507e43358bd21c8d115538a3
Autor:
Frances K. Shepherd, Shanley N. Roach, Autumn E. Sanders, Yanan Liu, Dira S. Putri, Rong Li, Nathan Merrill, Mark J. Pierson, Sergei V. Kotenko, Zhongde Wang, Ryan A. Langlois
Publikováno v:
mBio, Vol 15, Iss 10 (2024)
ABSTRACT When a virus crosses from one host species to another, the consequences can be devastating. However, animal models to empirically evaluate cross-species transmission can fail to recapitulate natural transmission routes, physiologically relev
Externí odkaz:
https://doaj.org/article/18dd9cd31dc1477fbe597f54b11b48ae
Autor:
Sabine Schmid, Miguel Garcia, Luna Zhan, Sierra Cheng, Khaleeq Khan, Maisha Chowdhury, Amir Sabouhanian, Joshua Herman, Preet Walia, Evan Strom, M. Catherine Brown, Devalben Patel, Wei Xu, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Penelope A. Bradbury, Geoffrey Liu, David Shultz
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e37082- (2024)
Background: We evaluated outcomes in non-small cell lung cancer (NSCLC) patients who presented with brain-only metastatic (BOM) disease overall and by EGFR/ALK mutation status. Methods: We analyzed clinico-demographic, treatment and survival data for
Externí odkaz:
https://doaj.org/article/352ab0135e9c44e28fc79f4a1ecff8a6
Autor:
Ruth Moulson, Jennifer Law, Adrian Sacher, Geoffrey Liu, Frances A. Shepherd, Penelope Bradbury, Lawson Eng, Sandra Iczkovitz, Erica Abbie, Julia Elia-Pacitti, Emmanuel M. Ewara, Viktoriia Mokriak, Jessica Weiss, Christopher Pettengell, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1947-1960 (2024)
Real-world evidence for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) in Canada is limited. This study’s objective was to use previously validated DARWENTM artificial intelligence (AI) to extract data from electronic heath
Externí odkaz:
https://doaj.org/article/fcfae28c3a5541b497cdc9f018c04ea0
Autor:
Autumn E. Sanders, Henriette Arnesen, Frances K. Shepherd, Dira S. Putri, Jessica K. Fiege, Mark J. Pierson, Shanley N. Roach, Harald Carlsen, David Masopust, Preben Boysen, Ryan A. Langlois
Publikováno v:
mSphere, Vol 9, Iss 2 (2024)
ABSTRACT Specific pathogen-free (SPF) laboratory mice dominate preclinical studies for immunology and vaccinology. Unfortunately, SPF mice often fail to accurately model human responses to vaccination and other immunological perturbations. Several gr
Externí odkaz:
https://doaj.org/article/87adcac41ea74783bc1ecd64e40dff96
Autor:
Rakesh Kumar, Keunchil Park, Frances A Shepherd, John V Heymach, Quincy Chu, Sylvia Hartl, J Carl Barrett, Sonia Iyer, Parneet Cheema, Marianna Koczywas, Maximilian Hochmair, Giuseppe Galletti, Mark Gustavson, Brent Evans, Jan Cosaert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fc6c2d7f62824e51983bea009bbe51ac
Autor:
Sally C.M. Lau, MD, MPH, Kirstin Perdrizet, MD, Andrea S. Fung, MD, PhD, Danilo Giffoni M.M. Mata, MD, Jessica Weiss, PhD, Nick Holzapfel, MD, Geoffrey Liu, MD, Penelope A. Bradbury, MD, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc, Harriet Feilotter, MD, Brandon Sheffield, MD, David Hwang, MD, Ming Sound Tsao, MD, Susanna Cheng, MD, Parneet Cheema, MD, Natasha B. Leighl, MD, MMSc
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100562- (2023)
Introduction: NSCLC with MET exon 14 skipping mutation (METex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatm
Externí odkaz:
https://doaj.org/article/1c185004b807431a8e7cb5c371cc5890
Autor:
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A. Shepherd, Krishna C. Bulusu, Gianluca Laus, Barbara Collins, J. Carl Barrett, Ryan J. Hartmaier, Vassiliki Papadimitrakopoulou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-8 (2023)
In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCL
Externí odkaz:
https://doaj.org/article/97023c9e42e0450eab3688b9d4689761
Autor:
Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4428-4437 (2022)
In advanced non-small cell lung cancer (NSCLC), patients with actionable genomic alterations may derive additional clinical benefit from targeted treatment compared to cytotoxic chemotherapy. Current guidelines recommend extensive testing with next g
Externí odkaz:
https://doaj.org/article/1eeb191a55df4e19870dc32a209c27eb